Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs
HONG KONG, March 9, 2021 /PRNewswire/ -- Insilico Medicine, an AI drug discovery company, announced that UCB will integrate Insilico'sChemistry42™ into UCB's internal drug discovery pipeline. UCB's early adoption of Insilico Medicine's proprietary technology will provide UCB's scientists with the...
Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study
- 80 to 100% of BE ABLE 1 responders maintained a response of at least 90% disease improvement (PASI90) over 60 weeks with bimekizumab - These positive results mark the longest-term data to date demonstrating durable PASI90/PASI100 outcomes to 60 weeks with investigational molecule bimekizumab, ...
New Data Affirms Strength of UCB Immuno-Dermatology Portfolio
BRUSSELS, March 1, 2019 /PRNewswire/ -- UCB, a global biopharmaceutical company, will present results from the clinical development program of the company's key pipeline molecule, bimekizumab, a novel humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-17A and IL-...
